Want to see AU:VIT full AI Analyst Report?
Top Page
Cronos Australia Ltd.
(Sydney:VIT)
Select Model
Select Model
Rating:51Neutral
Price Target:
AU$0.03
▼(-13.33% Downside)
Action:Reiterated
Date:08/27/26
The score is primarily held back by weakening financial performance—most notably the swing to a net loss and the move to negative operating/free cash flow—despite a relatively supportive balance sheet. Technicals add additional caution due to a broader downtrend (below key moving averages) and negative MACD. Valuation provides partial support through a strong dividend yield, but the P/E is not compelling enough to outweigh the recent operating deterioration.
Positive Factors
Revenue growth and operating scale
Continued revenue expansion indicates the company has built meaningful operating scale and market reach. Although growth alone does not offset current margin pressure, a larger revenue base can support future profitability if execution and cost control improve.
Negative Factors
Sharp profitability deterioration
The move from profit to loss signals substantial margin pressure and weakens earnings quality. Persistent gross-profit deterioration could constrain reinvestment, reduce financial flexibility, and make future results more volatile until operating economics recover.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and operating scale
Continued revenue expansion indicates the company has built meaningful operating scale and market reach. Although growth alone does not offset current margin pressure, a larger revenue base can support future profitability if execution and cost control improve.
Read all positive factors
Cronos Australia Ltd. (VIT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$20.54M
Dividend Yield7.69%
Average Volume (3M)228.84K
Price to Earnings (P/E)21.7
Beta (1Y)1.56
Revenue Growth5.74%
EPS Growth-222.22%
CountryAU
Employees72
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding662,741,800
10 Day Avg. Volume238,134
30 Day Avg. Volume228,844
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cronos Australia Ltd. Business Overview & Revenue Model
Company Description
Established in 2018 and based in South Yarra, Australia, Vitura Health Limited focuses on the supply and marketing of medicinal cannabis goods throughout Australia and the Asian market. The company manages a portfolio of key brands, such as CanVie...
Cronos Australia Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
68
Positive
Cash Flow
35
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 131.16M | 124.04M | 123.87M | 117.34M | 66.99M |
| Gross Profit | 3.92M | 33.75M | 34.22M | 25.96M | 25.43M |
| EBITDA | 1.20M | 5.64M | 7.08M | 21.08M | 10.87M |
| Net Income | -4.39M | 3.32M | 3.51M | 13.81M | 6.05M |
Balance Sheet | |||||
| Total Assets | 76.74M | 75.49M | 71.28M | 46.90M | 42.87M |
| Cash, Cash Equivalents and Short-Term Investments | 5.35M | 7.58M | 11.35M | 18.85M | 16.08M |
| Total Debt | 16.40M | 11.97M | 11.02M | 1.71M | 5.06M |
| Total Liabilities | 33.80M | 27.89M | 32.84M | 11.99M | 16.79M |
| Stockholders Equity | 43.55M | 48.20M | 38.78M | 34.98M | 26.10M |
Cash Flow | |||||
| Free Cash Flow | -216.80K | 2.58M | 6.21M | 8.78M | 13.13M |
| Operating Cash Flow | -91.02K | 2.67M | 7.00M | 9.71M | 13.50M |
| Investing Cash Flow | -3.74M | -13.87M | -13.20M | -837.72K | 2.00M |
| Financing Cash Flow | 1.60M | 7.43M | -1.30M | -6.10M | -1.50M |
Cronos Australia Ltd. Technical Analysis
Positive
0.03
Price Trends
0.03
Positive
0.03
Negative
0.04
Negative
Market Momentum
>-0.01
Negative
62.31
Neutral
101.59
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VIT, the sentiment is Positive. The current price of 0.03 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 62.31 is Neutral, neither overbought nor oversold. The STOCH value of 101.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VIT.
Cronos Australia Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$151.15M | 13.80 | 19.91% | 4.33% | 12.19% | 22.36% | |
55 Neutral | AU$57.96M | -14.78 | -1.67% | ― | 15.21% | -141.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$20.54M | 21.67 | 1.66% | 6.67% | 5.74% | -222.22% | |
50 Neutral | AU$2.90M | -0.33 | -76.30% | ― | 3.64% | -23.56% | |
48 Neutral | AU$4.98M | 0.35 | 93.89% | ― | -29.95% | ― | |
39 Underperform | AU$20.02M | -5.07 | 4388.00% | ― | -53.90% | 57.52% |
* Healthcare Sector Average
AU:VIT
Cronos Australia Ltd.
0.03
-0.04
-61.19%
AU:EXL
Elixinol Wellness
0.02
>-0.01
-11.76%
AU:CAN
Cann Group
0.01
>-0.01
-16.67%
AU:VLS
Vita Life Sciences Limited
2.79
0.57
25.51%
AU:LGP
Little Green Pharma Ltd.
0.07
-0.05
-43.33%
AU:PKP
Althea Group Holdings Ltd.
0.01
>-0.01
-33.33%
Cronos Australia Ltd. Corporate Events
Vitura Health pivots to disciplined growth after profit slump in FY2026
Aug 26, 2026
Vitura reported FY2026 operating revenue of $131.2 million, up 5.7% year-on-year, driven by higher unit volumes, strong growth in clinics and services, and more than doubled nicotine vaping product revenue. However, normalised EBITDA fell to $3.0 ...
Vitura Health Files 2026 Corporate Governance Statement with ASX
Aug 26, 2026
Vitura Health Limited has lodged its annual corporate governance statement for the financial year ended 30 June 2026, confirming that the document is current as of 25 August 2026 and approved by the board. The statement is contained within its fin...
Vitura Health Slips to Loss as Cannabis Price Compression Squeezes Margins
Aug 25, 2026
Vitura Health reported a consolidated loss after tax of about $4.4 million for the year to 30 June 2026, reversing a prior-year profit despite a 5.7% rise in revenue to $131.2 million driven by growth in product distribution and medical consultati...
Vitura Health Tightens Capital Structure as Rights and Options Lapse
Jul 27, 2026
Vitura Health Limited has notified the market of changes to its issued capital, with more than 4 million performance rights and options ceasing on 27 July 2026. The lapse of conditional performance rights and expiry of unexercised options reduces ...
Vitura reshapes leadership team to cut costs and sharpen patient focus
Jul 22, 2026
Vitura Health Limited has announced two senior appointments as part of a broader leadership and structural overhaul designed to boost efficiency and sharpen its patient-focused strategy. James Frayne will join as Chief Financial Officer, bringing ...
Vitura Health Updates Corporate Address as Digital Health Network Expands
Jul 8, 2026
Vitura Health Limited has updated its registered office and principal place of business to new premises in South Yarra, Victoria, while keeping its website and contact details unchanged. The move consolidates the company’s corporate presence...
Vitura installs interim CFO as CEO launches finance leadership overhaul
Jun 4, 2026
Vitura Health has appointed former long-serving finance chief Tom Howitt as interim CFO following the resignation of Andrew Cook, who departed during his probationary period to pursue an external senior role aligned with his long-term career goals...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.